Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Processa Pharmaceuticals announced participation in two upcoming investor conferences to discuss its lead BTK inhibitor drug candidate VT-7208 and recent acquisition of Vidya Therapeutics. The company completed a $200 million private placement to support development across immune-mediated diseases and plans special shareholder meetings for preferre…
RedHill Biopharma announced it has acquired exclusive global and U.S. commercialization rights to Ferring Pharmaceuticals' two FDA-approved gastrointestinal drugs, Rebyota and Clenpiq, in a transformative deal secured through proceeds from its prior Talicia divestiture. These drugs collectively generated about $37.5 million in U.S. net sales in 202…
Upstream Bio plans to initiate pivotal Phase 3 trials in Q1 2027 for verekitug, a novel TSLP receptor antagonist, in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The trials will evaluate a 400 mg dose administered every 12 weeks versus placebo, targeting broad patient populations. Successful Phase 3 results could lead to FDA…
Jade Biosciences, a clinical-stage biotech focused on autoimmune diseases, announced its participation in several upcoming investor conferences, including Wells Fargo, Citi, HC Wainwright, and Stifel events in September 2026. The company will host fireside chats and one-on-one meetings to discuss its pipeline, including lead product candidate JADE1…
Seres Therapeutics, a clinical-stage biotechnology company specializing in live biotherapeutics, announced its participation in the H.C. Wainwright Investment Conference and will provide an overview of its pipeline including SER-155 and SER-603. The company continues to develop treatments targeting oncology-related microbiome therapies and inflamma…
Harrow, Inc., a Nasdaq-listed North American ophthalmic disease management company, announced its management participation in three investor conferences in New York City during September 2026, featuring fireside chats and one-on-one investor meetings. The events aim to provide updates on company strategy and market presence.
Auddia Inc., a US-listed AI-first technology company, announced that its subsidiary Influence Healthcare has signed a Letter of Intent to sublease and eventually master lease a 24,000 sq ft specialty hospital in Texas with four operating rooms. This marks a significant milestone in Influence Healthcare's growth strategy and the company's broader pl…
Immunocore Holdings plc announced that its management team will participate in multiple investor conferences in September 2026, including Cantor Global Healthcare, Morgan Stanley Global Healthcare, Baird Global Healthcare, and H.C. Wainwright Investment conferences. The sessions will include fireside chats and small group meetings, focusing on the …
Beam Therapeutics has appointed Eric Foster as Chief Commercial Officer to lead its commercial strategy and operations as the company progresses toward launching multiple precision genetic medicines, including the potential 2027 launch of risto-cel. Foster brings over 25 years of leadership experience in specialty and rare disease markets, enhancin…
Parabilis Medicines announced that its Chairman, President and CEO, Dr. Mathai Mammen, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The company focuses on developing novel alpha-helical peptides called Helicons targeting intracellular proteins previously considered undruggable, with lead drug c…
BioCryst Pharmaceuticals, a biotechnology company specializing in treatments for rare diseases including hereditary angioedema, announced it will present at the Morgan Stanley 24th Annual Global Healthcare Conference. The presentation is scheduled for September 15, 2026, and will be webcast live. BioCryst currently markets ORLADEYO, its oral plasma…
Axogen, Inc., a leader in peripheral nerve repair technology, announced its participation in the 24th Annual Morgan Stanley Global Healthcare Conference, highlighting its commitment to innovative surgical solutions for nerve regeneration.
Rank One Computing Corporation (ROC), a U.S.-based Vision AI company, has finalized its acquisition of Zuccaro Technical Consulting LLC (ZTC). This acquisition integrates ZTC's digital forensics expertise and federal customer relationships into ROC's unified Vision AI platform, expanding ROC Evidence into a comprehensive investigative intelligence …
Tango Therapeutics, a clinical-stage biotech company focused on precision oncology therapies, will present at the 2026 Cantor Global Healthcare Conference. The company is advancing cancer treatments through synthetic lethality targets and will webcast its management discussion.
Aya Gold & Silver Inc. announced an agreement to acquire a 139 km² copper-silver exploration portfolio, including a 19 km² mining license, in Morocco near its Zgounder Silver Mine. The acquisition aims to consolidate Aya's land holdings in the region and provide exposure to a large, underexplored copper-silver system with multiple mineralization ty…
NOVONIX Limited announces that its Riverside synthetic graphite anode material manufacturing project has been chosen for inclusion in a South Korea-U.S. government-led infrastructure initiative. This program connects U.S. projects with Korean companies, investors, and financing partners, promoting collaboration and accelerating development of criti…
Tenax Therapeutics, a clinical-stage pharmaceutical company focusing on cardiopulmonary therapies, announced that CEO Chris Giordano will present at the upcoming 2026 Cantor Global Healthcare Conference. The company is developing levosimendan for treating pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), a conditi…
Lightbridge Corporation announced that the Japan Patent Office has granted a Notice of Allowance for its multi-zone fuel element patent, covering the fuel rod design, fuel assembly, and 3D printing production method. This patent extends protection of Lightbridge's advanced nuclear fuel technology into the significant Japanese nuclear market, aligni…
Electra Battery Materials Corporation has appointed Douglas Geniti as Senior Advisor, Commercial Strategy to support the commercial execution of its North American cobalt sulfate refinery. With over 35 years of experience in cobalt and nickel markets, Geniti will aid feedstock strategy, customer engagement, and product marketing as Electra advances…
Syndax Pharmaceuticals announced that its CEO and management team will participate in important investor conferences in September 2026, including the Citi 2026 Biopharma Back to School Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company highlighted its FDA-approved cancer therapies and ongoing clinical trials.
BlossomHill Therapeutics announced updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643, a novel OMNI-EGFR inhibitor targeting EGFR-mutant non-small cell lung cancer (NSCLC) with secondary resistance mutations including C797S. Data will be presented at the 2026 World Conference on Lung Cancer. BH-30643 has received FDA Fast Track design…
Aquestive Therapeutics, a pharmaceutical company specializing in innovative drug delivery technologies, will participate in four investor conferences in September 2026 to present its business updates and development programs. The company highlighted its proprietary products including Anaphylm sublingual film and AQST-108 topical gel, and will provi…
Kymera Therapeutics announced the completion of enrollment for its KT-621 BROADEN2 Phase 2b trial in atopic dermatitis (AD), with topline data expected by the end of 2026 and plans to start Phase 3 trials by mid-2027. Additionally, a parallel Phase 2b trial in asthma is ongoing with results anticipated in late 2027. KT-621 is a first-in-class oral …
Advanced Micro Devices pulled back after recent earnings noise. The business fundamentals - large market cap, strong free cash flow, low leverage and exposure to AI/data center demand - support a tactical long. Valuation is rich, so this is a measured trade with defined stop and a mid-term horizon to ride a re-rating or volatility-driven mean rever…
Park Hotels & Resorts shares rose in pre-market trading following a BMO Capital Markets upgrade and a higher price target, building on recent earnings that topped expectations and analyst revisions from other firms. The company’s planned use of a delayed draw loan to address upcoming maturities has also been cited as a supporting factor for investo…
